{"id":454715,"date":"2021-03-10T08:18:07","date_gmt":"2021-03-10T13:18:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454715"},"modified":"2021-03-10T08:18:07","modified_gmt":"2021-03-10T13:18:07","slug":"cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/","title":{"rendered":"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications<\/b><\/p>\n<p>OXNARD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCURE Pharmaceutical Holding Corp. (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline.\n<\/p>\n<p>\nThe first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm\u00ae, CURE\u2019s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known anti-seizure API for both adult and pediatric indications. These programs will leverage existing pre-clinical\/clinical safety and toxicity data to develop orally bioavailable products and expand the Company\u2019s pharmaceutical research &amp; development efforts toward building a specialty pharmaceutical pipeline.\n<\/p>\n<p>\n\u201cWe are leveraging our validated drug technology platform, currently in use in a variety of consumer markets as well as our CUREfilm\u00ae Blue clinical program, to enhance shareholder value via this pipeline expansion,\u201d said Rob Davidson, CEO of CURE. \u201cAs we looked to expand our pharmaceutical pipeline, we used a very methodical approach to product selection, striving to best differentiate ourselves as a pharmaceutical researcher and product developer. By working with known APIs and applying them using our CUREform\u2122 platform, similar to how we have approached our Sildenafil program, we amplify our market opportunities in an important and relevant way by increasing the probability of approval and speed to market.\u201d\n<\/p>\n<p>\n\u201cWe are strategically expanding our pipeline and research and development efforts into new strategic focus areas including antiviral and anti-seizure therapeutics, following a similar pathway to human clinical trials as our CUREfilm\u00ae Blue clinical program,\u201d said Jonathan Berlent, Chief Business Officer. \u201cWe believe applying our film technology to high-impact, high unmet need areas is both intuitively strategic and therapeutically relevant to patients. We hope to ultimately bring products to market faster and more efficiently.\u201d\n<\/p>\n<p>\nCURE recently announced the start of its initial Pharmacokinetics (PK)\/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Sildenafil Citrate oral dispersible product known as CUREfilm\u00ae blue. This application, as well as these additional pipeline products are anticipated to be initiated via the 505(b)(2) drug approval pathway, with both Academic and Industry partnerships anticipated to facilitate the most intuitive path to commercialization.\n<\/p>\n<p><b>About CURE Pharmaceutical Holding Corp<br \/>\n<br \/><\/b>CURE Pharmaceutical<sup>\u00ae<\/sup> is the pioneering developer of CUREform\u2122, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.\n<\/p>\n<p>\nAs a vertically integrated company, CURE\u2019s 25,000 square foot, FDA-registered, NSF<sup>\u00ae<\/sup> and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.\n<\/p>\n<p><sup>1 <\/sup>Viagra<sup>\u00ae<\/sup> is a registered trademark of Pfizer Inc.\n<\/p>\n<p><b><i>Forward Looking Statement<br \/>\n<br \/><\/i><\/b><i>Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (\u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended (\u201cExchange Act\u201d), which are usually identified by the use of words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE\u2019s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210310005336\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210310005336\/en\/<\/a><\/span><\/p>\n<p>\nLicensing Contact:<br \/>\n<br \/>Jonathan Berlent<br \/>\n<br \/>Chief Business Officer<br \/>\n<br \/>CURE Pharmaceutical<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Jberlent@curepharma.com\">Jberlent@curepharma.com<br \/>\n<\/a><br \/>516.660.9148<\/p>\n<p>Investment Contact:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@curepharma.com\">investors@curepharma.com<br \/>\n<\/a><\/p>\n<p>Gary Zwetchkenbaum<br \/>\n<br \/>Plum Tree Consulting LLC<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:gzplumtree@gmail.com\">gzplumtree@gmail.com<br \/>\n<\/a><br \/>516.455.7662<\/p>\n<p>Media Contact:<br \/>\n<br \/>Kathryn Brown<br \/>\n<br \/>CMW Media<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cure@cmwmedia.com\">cure@cmwmedia.com<br \/>\n<\/a><br \/>858.264.6600\n<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> FDA Alternative Medicine Health Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211; CURE Pharmaceutical Holding Corp. (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm\u00ae, CURE\u2019s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454715","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211; CURE Pharmaceutical Holding Corp. (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm\u00ae, CURE\u2019s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known &hellip; Continue reading &quot;CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T13:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications\",\"datePublished\":\"2021-03-10T13:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/\"},\"wordCount\":902,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/\",\"name\":\"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-10T13:18:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/","og_locale":"en_US","og_type":"article","og_title":"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications - Market Newsdesk","og_description":"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211; CURE Pharmaceutical Holding Corp. (\u201cCURE\u201d or the \u201cCompany\u201d) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding products to its growing pharmaceutical pipeline. The first is an antiviral clinical development program where the Company will look to load a known active pharmaceutical ingredient (API) onto its patented drug delivery platform CUREfilm\u00ae, CURE\u2019s oral thin film platform that optimizes the absorption and metabolism of therapeutic actives. The second pipeline product addition uses a similar bioequivalence approach where the Company will formulate the delivery of a known &hellip; Continue reading \"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T13:18:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications","datePublished":"2021-03-10T13:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/"},"wordCount":902,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/","name":"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-10T13:18:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210310005336r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-announces-addition-of-two-new-clinical-development-programs-targeting-anti-seizure-and-antiviral-applications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454715"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454715\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}